Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysine acetyltransferase 14 (KAT14) is a nuclear enzyme encoded by the KAT14 gene in humans. It is a component of the ADA2A-containing ATAC histone acetyltransferase complex, involved in acetylating histones H3 and H4 to promote chromatin organization and transcriptional regulation. KAT14 plays a role as a scaffold supporting ATAC complex stability and is required for normal cell cycle progression, especially through the G1 and G2/M phases[1][5]. The protein binds to LIM domains of CSRP2 and has weak intrinsic acetyltransferase activity. Diseases associated with alterations in KAT14 include mitochondrial complex IV deficiency and Buruli ulcer, and it may participate in fibrotic disease mechanisms[1][6]. KAT14 is expressed predominantly in the nucleus with alternative spliced variants described[3]. *No specific drugs, biomarkers, or safety concerns are reported for KAT14 as of current publicly indexed sources.*
Acetylation of lysines on core histones, modulating chromatin accessibility and transcription Effects may be mediated through targeting the ATAC complex for epigenetic modulation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysine acetyltransferase 14 (KAT14).